Skip to main content

Table 4 Odds ratios for risk of worsening or improvement in EQ-5D anxiety/depression dimension when pain/discomfort dimension worsens or improves, respectively (not by treatment)

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

 

Odds ratio (95% CI)

Week 13 (n = 1403)

Week 25 (n = 1087)

Week 37 (n = 914)

Week 49 (n = 770)

Week 61 (n = 625)

Worsening of Anxiety/Depression with worsening Pain/Discomfort

2.495 (1.749–3.559)

3.623 (2.426–5.410)

2.259 (1.431–3.564)

2.696 (1.690–4.303)

1.457 (0.832–2.554)

Improvement in Anxiety/Depression with improvement in Pain/Discomfort

2.514 (1.591–3.972)

1.890 (1.159–3.083)

2.937 (1.738–4.964)

2.916 (1.643–5.177)

2.789 (1.380–5.638)

  1. CI confidence interval